Axos Financial Inc. (AX) reported robust second-quarter earnings for fiscal 2026, highlighted by a 23.3% surge in earnings per share and significant loan portfolio expansion, even as it manages industry-wide margin pressures and rising operational costs.
AppFolio Inc. reported a 22% year-over-year revenue surge in its fourth quarter, driven by AI innovation and premium product adoption, while navigating industry-wide cost pressures. The company also issued optimistic guidance for 2026.
Buoyed by a banner 2025 and surging consumer appetite for ocean voyages, Royal Caribbean Group forecasts double-digit profit growth for 2026, signaling a full-throttle recovery for the cruise industry.
Expedia Group has filed a WARN notice confirming 162 job cuts at its Seattle headquarters and among remote staff, marking the latest in a series of layoffs as the company accelerates its AI transformation amid intensifying industry competition.
Activist investment firm Tsai Capital has taken a stake in QXO, spotlighting the distributor's ambitious plan to consolidate the fragmented building products industry. The move comes as QXO's stock shows strong recent momentum despite longer-term headwinds.
As OpenAI accelerates toward a potential year-end IPO, Amazon, Microsoft, and Nvidia are in advanced talks to lead a funding round that could exceed $100 billion, reshaping the AI industry's financial and competitive landscape.
The Trump administration has issued a broad license allowing U.S. entities to engage in key oil activities in Venezuela, a major sanctions relief step aimed at jumpstarting the nation's crippled energy industry under its new U.S.-backed leadership.
Coty Inc.'s shares have tumbled nearly 60% over the past year, trading at a steep discount to industry peers. While a discounted cash flow model suggests significant undervaluation, the prolonged weakness raises questions about the cosmetics giant's turnaround narrative and whether the market is missing a hidden gem.
In a landmark move, Venezuela's parliament has passed reforms to its hydrocarbons law, easing state control and aiming to lure back foreign capital to its struggling oil industry, coinciding with a partial easing of U.S. sanctions.
After years of lackluster performance, Digistar Corporation Berhad (KLSE:DIGISTA) is showing early signs of a operational turnaround, marked by a notable improvement in its return on capital employed. While still trailing the industry average, the shift from losses to profitability on a reduced capital base offers a glimmer of hope for the battered stock.
The U.S. government's $1.6 billion commitment to USA Rare Earth signals a strategic pivot towards fostering competition in the critical minerals sector, reducing price supports and introducing new volatility. As policy shifts, industry leader MP Materials counters with record production and expanded magnet manufacturing, highlighting the intensifying race to secure a domestic supply chain for EVs and defense.
All eyes are on AbbVie as it prepares to release its fourth-quarter earnings. With a history of topping revenue forecasts, the market watches to see if its strategic shifts can continue to deliver amid evolving industry pressures.
Vera Therapeutics appoints industry veteran Matt Skelton as Chief Commercial Officer, signaling a strategic pivot toward commercialization as its lead drug candidate for IgA nephropathy, atacicept, undergoes FDA Priority Review.
Aerospace and defense component maker Woodward, Inc. (WWD) is commanding investor attention following a robust first-quarter earnings beat, a significant dividend hike, and an upgraded full-year outlook. The strong results have propelled the stock to new highs, reigniting the debate over its valuation in a rapidly evolving industry.
As Vishay Intertechnology prepares to release its fourth-quarter results, investors are weighing the chipmaker's recent performance against a backdrop of industry-wide gains and mixed signals from peers.
The adhesive and materials giant is expected to post modest revenue growth as investors gauge its resilience against a backdrop of uneven results from packaging industry peers.
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
Shares of building technologies giant Johnson Controls International have surged over 60% in the past year, dramatically outperforming the broader market. As the stock hovers near $123, investors are grappling with a critical question: does the current price reflect the company's true value, or has momentum outpaced fundamentals? A deep dive into valuation metrics suggests caution may be warranted.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
As the healthcare industry accelerates its shift to value-based care, Privia Health Group's physician-enablement platform is drawing investor attention for its scalable, asset-light approach and strong financial profile, with some analysts seeing significant upside potential.
